{
    "nct_id": "NCT03523585",
    "official_title": "A Phase 3, Multicenter, Randomized, Open-label, Active-controlled Study of Trastuzumab Deruxtecan (DS-8201a), an Anti-HER2-antibody Drug Conjugate, Versus Treatment of Investigator's Choice for HER2-positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With T-DM1",
    "inclusion_criteria": "* Is the age of majority in their country\n* Has pathologically documented breast cancer that:\n\n  1. is unresectable or metastatic\n  2. has confirmed HER2-positive expression as determined according to American Society of Clinical Oncology - College of American Pathologists guidelines evaluated at a central laboratory\n  3. was previously treated with ado-trastuzumab emtansine (T-DM1)\n* Has documented radiologic progression (during or after most recent treatment or within 6 months after completing adjuvant therapy)\n* Is HER2 positive as confirmed by central laboratory assessment of most recent tumor tissue sample available. If archived tissue is not available, agrees to provide a fresh biopsy.\n* Male and female participants of reproductive/childbearing potential must agree to use a highly effective form of contraception or avoid intercourse during and upon completion of the study and for at least:\n\n  1. 7 months after the last dose of DS-8201a (females); 4.5 months after last dose of DS-8201a (males)\n  2. 6 months after the last dose of lapatinib/capecitabine for female participants (3 months for male participants)\n  3. 7 months after the last dose of trastuzumab/capecitabine\n* Has adequate hematopoietic, renal and hepatic functions\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Has previously participated in an antibody drug conjugate study sponsored by Daiichi Sankyo. Prior treatment in the adjuvant/neo-adjuvant setting would be allowed if progression of disease did not occur within 12 months of end of adjuvant therapy\n* Has had prior treatment with capecitabine\n* Has uncontrolled or significant cardiovascular disease\n* Has a history of (noninfectious) interstitial lung disease (ILD)/pneumonitis that required steroids, has current ILD/pneumonitis, or suspected ILD/pneumonitis that cannot be ruled out by imaging at screening\n* Has active central nervous system (CNS) metastases",
    "miscellaneous_criteria": ""
}